Quick Answer
Atara Biotherapeutics, Inc. reported Operating Income Loss of $35.86 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed an increase of +143.0% in Operating Income Loss from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Atara Biotherapeutics, Inc.'s Operating Income Loss has grown by 516.3%.
- Historical annual values: Fiscal year 2025: $35.86 million | Fiscal year 2024: -$83.44 million | Fiscal year 2023: -$276.01 million | Fiscal year 2022: -$280.51 million | Fiscal year 2021: -$340.46 million | Fiscal year 2020: -$309.05 million | Fiscal year 2019: -$295.68 million | Fiscal year 2018: -$237.11 million | Fiscal year 2017: -$121.53 million | Fiscal year 2016: -$81.24 million | Fiscal year 2015: -$58.45 million | Fiscal year 2014: -$28.16 million | Fiscal year 2013: -$8.62 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: